IL17A and psoriasis: Reviewing literature published between 2020 and July 2023 showed that studies on the (cost-)effectiveness and/or safety of biologic DR in psoriasis are still scarce, especially regarding the newest generation biologics IL-17 and IL-23 inhibitors.